WSE:BLR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record.

Share Price & News

How has BLIRT's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLR is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 27% a week.

Volatility Over Time: BLR's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of Polish stocks.


Market Performance


7 Day Return

-9.1%

BLR

-8.0%

PL Biotechs

1.3%

PL Market


1 Year Return

1,509.5%

BLR

224.3%

PL Biotechs

-5.4%

PL Market

Return vs Industry: BLR exceeded the Polish Biotechs industry which returned 219.7% over the past year.

Return vs Market: BLR exceeded the Polish Market which returned -5.8% over the past year.


Shareholder returns

BLRIndustryMarket
7 Day-9.1%-8.0%1.3%
30 Day-46.2%-18.5%15.8%
90 Day113.9%-14.4%2.0%
1 Year1,509.5%1,509.5%224.3%224.3%-4.6%-5.4%
3 Year1,590.0%1,590.0%248.8%248.1%-14.2%-19.4%
5 Year813.5%813.5%22.0%21.0%6.0%-5.9%

Long-Term Price Volatility Vs. Market

How volatile is BLIRT's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BLIRT undervalued compared to its fair value and its price relative to the market?

38.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BLR (PLN16.9) is trading below our estimate of fair value (PLN27.4)

Significantly Below Fair Value: BLR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLR is good value based on its PE Ratio (51.3x) compared to the PL Biotechs industry average (95.3x).

PE vs Market: BLR is poor value based on its PE Ratio (51.3x) compared to the Polish market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLR is overvalued based on its PB Ratio (21.3x) compared to the PL Biotechs industry average (6.1x).


Next Steps

Future Growth

How is BLIRT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIRT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BLIRT performed over the past 5 years?

39.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLR has high quality earnings.

Growing Profit Margin: BLR's current net profit margins (24.1%) are higher than last year (5.7%).


Past Earnings Growth Analysis

Earnings Trend: BLR has become profitable over the past 5 years, growing earnings by 39.4% per year.

Accelerating Growth: BLR's earnings growth over the past year (880.8%) exceeds its 5-year average (39.4% per year).

Earnings vs Industry: BLR earnings growth over the past year (880.8%) exceeded the Biotechs industry 11.2%.


Return on Equity

High ROE: BLR's Return on Equity (41.6%) is considered outstanding.


Next Steps

Financial Health

How is BLIRT's financial position?


Financial Position Analysis

Short Term Liabilities: BLR's short term assets (PLN14.3M) exceed its short term liabilities (PLN3.3M).

Long Term Liabilities: BLR's short term assets (PLN14.3M) exceed its long term liabilities (PLN303.0K).


Debt to Equity History and Analysis

Debt Level: BLR is debt free.

Reducing Debt: BLR has no debt compared to 5 years ago when its debt to equity ratio was 21.8%.

Debt Coverage: BLR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BLR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BLIRT current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLR's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Marian Popinigis

2.33yrs

Tenure

Mr. Marian Popinigis has been the Chief Executive Officer at BLIRT S.A. since July 2018. He is President of the Managemement Board at BLIRT S.A. Mr. Popinigis is a Co-Founder of Mercor S.A. and serves as i...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BLIRT S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BLIRT S.A.
  • Ticker: BLR
  • Exchange: WSE
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł290.621m
  • Shares outstanding: 17.20m
  • Website: https://www.blirt.eu

Number of Employees


Location

  • BLIRT S.A.
  • Trzy Lipy 3/1.38
  • Gdansk
  • 80-172
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLRWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNMar 2011

Biography

BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland. The company offers a suite of services, including the des...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 18:10
End of Day Share Price2020/11/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.